keyword
https://read.qxmd.com/read/37252199/cost-effectiveness-of-aripiprazole-tablets-with-sensor-versus-oral-atypical-antipsychotics-for-the-treatment-of-schizophrenia-using-a-patient-level-microsimulation-modeling-approach
#1
JOURNAL ARTICLE
Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni, Jeffrey M Cochran
OBJECTIVE: Strategies designed to track drug ingestion may improve medication adherence and clinical outcomes in adults with schizophrenia. This study aimed to estimate the cost-effectiveness of aripiprazole tablets with sensor (AS; Abilify MyCite® ) versus generic oral atypical antipsychotics (AAPs) in schizophrenia from the United States payer and societal perspectives over 12 months. METHODS: An individual-level microsimulation was developed to generate individual trajectories using data from a phase 3b multicenter, open-label, mirror-image trial in adults with schizophrenia treated prospectively for 6 months with AS...
2023: ClinicoEconomics and Outcomes Research: CEOR
https://read.qxmd.com/read/35730516/letter-to-the-editor-rethinking-the-cost-of-antipsychotic-treatment-the-average-cost-of-the-drugs-used-in-turkey-in-2020
#2
JOURNAL ARTICLE
Mustafa Yıldız, Emre Osman
Dear Editor, The costs of antipsychotic drugs (APDs) used in the treatment of mental disorders with psychosis are mentioned in treatment guidelines (APA 2021, NICE 2014). While the American Psychiatric Association guideline states that every specialist should make decisions according to the rules and conditions of their country and their region, the National Institute of Health and Clinical Excellence guideline emphasizes that drug costs must be taken into consideration in the treatment process. Classical or first-generation antipsychotic drugs (FAPDs) are relatively cheaper in terms of sales prices compared to atypical or second-generation antipsychotic drugs (SAPDs) with a slightly different effect mechanism...
2022: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://read.qxmd.com/read/33586456/influence-of-cyp2d6-gene-polymorphisms-on-the-pharmacokinetics-of-aripiprazole-in-healthy-chinese-subjects
#3
JOURNAL ARTICLE
Xiaodan Zhang, Chengquan Liu, Shuang Zhou, Ran Xie, Xu He, Zhiqi Wang, Honghong Yi, You Shu, Zining Wang, Kun Hu, Lingyue Ma, Yimin Cui, Xia Zhao, Jin Xiang
Background: Pharmacogenetics study was added into 2 bioequivalence trials of aripiprazole. The correlation between CYP2D6 polymorphisms and aripiprazole pharmacokinetics (PK) was analyzed. Materials & methods: A total of 140 subjects were included. A total of 26 CYP2D6 gene alleles were detected. The plasma concentration of aripiprazole was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). SPSS Statistics 21 was used to analyze the correlation between CYP2D6 polymorphisms and aripiprazole PK parameters...
February 15, 2021: Pharmacogenomics
https://read.qxmd.com/read/32741865/-establishment-of-a-novel-method-to-evaluate-water-permeation-rates-by-combining-the-dynamic-contact-angle-and-thermographic-approach-significance-of-disintegration-properties-of-orally-disintegrating-tablets
#4
JOURNAL ARTICLE
Toyofumi Suzuki, Takumi Kurano, Takanori Kanazawa, Naoto Suzuki
The purpose of the present study was to establish a novel method to evaluate water penetration rates by combining the local dynamic contact angle and thermographic approach to characterize water conduction properties in orally disintegrating (OD) tablets. The OD tablet tester OD-mate was used to measure the disintegration times of OD tablets. Other formulation characteristics, such as tablet hardness and friability, were evaluated. By examining three formulation characteristics, such as the disintegration time, tablet hardness, and friability, of 33 OD tablets for generic drugs, four characteristic OD tablets containing aripiprazole were selected...
2020: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://read.qxmd.com/read/32639292/antidepressant-augmentation-a-review-of-the-literature-and-a-review-of-the-pharmacoeconomic-considerations
#5
REVIEW
Glenn Catalano, Rhonda A Robeel, Grace A Cheney, Benjamin C Spurling, Maria C Catalano, Susan K Schultz, Deborah L Sanchez
PURPOSE: Antidepressant augmentation strategies for treatment-resistant depression (TRD) are discussed here with an analysis of patient out-of-pocket costs for various medications. The choice of agent ranges from newer atypical antipsychotics (aripiprazole, brexpiprazole, quetiapine) to older agents including buspirone, liothyronine (T3), and lithium. We sought to better understand the differences among these agents to aid in clinical decision making. METHODS: We conducted a focused review of the support for each of the aforementioned agents in antidepressant augmentation...
2020: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/32576120/variability-in-price-of-generic-antipsychotic-medications-at-community-pharmacies
#6
JOURNAL ARTICLE
Carrie R Kriz, Leigh Anne Nelson, Lakshmi Venkitachalam, Jenifer E Allsworth, An-Lin Cheng, Roger W Sommi
OBJECTIVE: This study aimed to examine variability in pricing of generic antipsychotic medications in a diverse metropolitan area and to determine whether prices varied by pharmacy type. METHODS: A cross-sectional survey was conducted of pharmacy-level variability in retail cash prices for a 30-day supply of one first-generation and five generically available second-generation antipsychotic medications at community pharmacies in the Kansas City metropolitan area...
October 1, 2020: Psychiatric Services: a Journal of the American Psychiatric Association
https://read.qxmd.com/read/28005435/is-there-a-weight-neutral-second-generation-antipsychotic-for-bipolar-disorder
#7
REVIEW
Fang Fang, Zuowei Wang, Renrong Wu, Joseph R Calabrese, Keming Gao
Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial...
April 2017: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/26024955/important-clinical-features-of-atypical-antipsychotics-in-acute-bipolar-depression-that-inform-routine-clinical-care-a-review-of-pivotal-studies-with-number-needed-to-treat
#8
REVIEW
Keming Gao, Chengmei Yuan, Renrong Wu, Jun Chen, Zuowei Wang, Yiru Fang, Joseph R Calabrese
English-language literature cited in MEDLINE from January, 1980 to October 30, 2014 was searched by using terms of antipsychotic, generic and brand names of atypical antipsychotics, "bipolar depression/bipolar disorder", "placebo", and "trial". The parameters of response (≥50% improvement on MADRS, Montgomery-Asberg Depression Rating Scale total score), remission (either ≤12 or 8 on MADRS total score at endpoint), discontinuation due to adverse events (DAEs), somnolence, ≥7% weight gain, overall extrapyramidal side-effects (EPSs), and akathisia, were extracted from originally published primary outcome papers...
October 2015: Neuroscience Bulletin
https://read.qxmd.com/read/24456317/measuring-economic-impact-of-applying-daily-average-consumption-limits
#9
JOURNAL ARTICLE
Bridget M Flavin, Lynn M Nishida, Sean H Karbowicz, Mark E Renner, Ruth J Leonard
BACKGROUND: Health plans may achieve cost savings by limiting the daily average consumption (DACON) of certain medications and encouraging members and prescribers to select lower cost dosing options. Various strengths of a given medication may be similarly priced per unit; therefore, a single unit of a higher-strength medication may cost less than multiple lower-strength units that provide the same dose. For instance, a single 10 mg tablet may cost less than two 5 mg tablets.  OBJECTIVE: To measure the economic impact of implementing DACON limits for selected medications...
February 2014: Journal of Managed Care Pharmacy: JMCP
https://read.qxmd.com/read/24049452/long-term-cost-effectiveness-of-atypical-antipsychotics-in-the-treatment-of-adults-with-schizophrenia-in-the-us
#10
JOURNAL ARTICLE
Ken O'Day, Krithika Rajagopalan, Kellie Meyer, Andrei Pikalov, Antony Loebel
BACKGROUND: The purpose of this study was to evaluate the long-term cost-effectiveness (including hospitalizations and cardiometabolic consequences) of atypical antipsychotics among adults with schizophrenia. METHODS: A 5-year Markov cohort cost-effectiveness model, from a US payer perspective, was developed to compare lurasidone, generic risperidone, generic olanzapine, generic ziprasidone, aripiprazole, and quetiapine extended-release. Health states included in the model were patients: on an initial atypical antipsychotic; switched to a second atypical antipsychotic; and on clozapine after failing a second atypical antipsychotic...
2013: ClinicoEconomics and Outcomes Research: CEOR
https://read.qxmd.com/read/23724438/antipsychotic-drugs-and-breastfeeding
#11
REVIEW
Gil Klinger, Bracha Stahl, Paolo Fusar-Poli, Paul Merlob
OBJECTIVE: The incidence of psychotic disorders during the postpartum period is higher than at any other time during a women's life and coincides with the time when breastfeeding is most recommended. As a result, safety data on use of antipsychotic drugs during lactation is essential. Our aim was to analyze the medical literature for information on antipsychotic drug use during breastfeeding and to determine the safety of their use for the exposed infant. DATA SOURCES: Medline (U...
2013: Pediatric Endocrinology Reviews: PER
https://read.qxmd.com/read/21951966/geissoschizine-methyl-ether-has-third-generation-antipsychotic-like-actions-at-the-dopamine-and-serotonin-receptors
#12
JOURNAL ARTICLE
Takashi Ueda, Shinya Ugawa, Yusuke Ishida, Shoichi Shimada
Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders. It has improved its safety and tolerability profiles, and these effects have been attributed to its pharmacological profile at the serotonin 5-HT and dopamine D(2) receptors. To discover compounds that have a similar pharmacological profile, we introduced a generic single-cell-based calcium imaging assay that standardizes the readouts from various assays used in previous studies on aripiprazole. In the present assay, the efficacy and potency of known ligands of serotonin 5-HT(1A), 5-HT(2A), 5-HT(2C), 5-HT(7) and dopamine D(2L) receptors were comparable to those found in previous studies using a variety of readouts...
December 5, 2011: European Journal of Pharmacology
https://read.qxmd.com/read/21052983/number-needed-to-treat-analyses-of-drugs-used-for-maintenance-treatment-of-bipolar-disorder
#13
COMPARATIVE STUDY
Dina Popovic, Maria Reinares, Benedikt Amann, Manel Salamero, Eduard Vieta
RATIONALE: Due to the episodic and chronic nature of bipolar disorder (BD), maintenance therapy represents a critical part of treatment; however, there is a paucity of studies comparing effectiveness of available long-term treatments. OBJECTIVE: The aim of this study is to determine and compare the efficacy of pharmacological treatments for maintenance treatment of BD by means of the number needed to treat (NNT). METHODS: The efficacy of drugs used for maintenance treatment of BD, as emerging from the results of randomized controlled trials, was assessed using the size effect measure of NNT...
February 2011: Psychopharmacology
https://read.qxmd.com/read/21034695/number-needed-to-treat-to-harm-for-discontinuation-due-to-adverse-events-in-the-treatment-of-bipolar-depression-major-depressive-disorder-and-generalized-anxiety-disorder-with-atypical-antipsychotics
#14
COMPARATIVE STUDY
Keming Gao, David E Kemp, Elizabeth Fein, Zuowei Wang, Yiru Fang, Stephen J Ganocy, Joseph R Calabrese
OBJECTIVE: To estimate the number needed to treat to harm (NNTH) for discontinuation due to adverse events with atypical antipsychotics relative to placebo during the treatment of bipolar depression, major depressive disorder (MDD), and generalized anxiety disorder (GAD). DATA SOURCES: English-language literature published and cited in MEDLINE from January 1966 to May 2009 was searched with the terms antipsychotic, atypical antipsychotic, generic and brand names of atypical antipsychotics, safety, tolerability, discontinuation due to adverse events, somnolence, sedation, weight gain, akathisia, or extrapyramidal side effect; and bipolar depression, major depressive disorder, or generalized anxiety disorder; and randomized, placebo-controlled clinical trial...
August 2011: Journal of Clinical Psychiatry
https://read.qxmd.com/read/19594198/patients-attitudes-towards-generic-substitution-of-oral-atypical-antipsychotics-a-questionnaire-based-survey-in-a-hypothetical-pharmacy-setting
#15
JOURNAL ARTICLE
Beatriz Roman
BACKGROUND: Generic atypical antipsychotics in tablet form differ in name, appearance and packaging from the innovator brand antipsychotics. These differences might cause anxiety, confusion and misperceptions in some ambulant patients with psychoses/schizophrenia, especially if the brand atypical antipsychotic is substituted in the pharmacy without the acknowledgement of the patient and treating psychiatrist. Furthermore, generic substitution of branded oral atypical antipsychotics in the pharmacy might cause nonadherence and potentially lead to suboptimal treatment outcomes if patients perceive the medicines to be clinically different...
August 2009: CNS Drugs
https://read.qxmd.com/read/19389331/akathisia-an-updated-review-focusing-on-second-generation-antipsychotics
#16
REVIEW
John M Kane, Wolfgang W Fleischhacker, Lars Hansen, Roy Perlis, Andrei Pikalov, Sheila Assunção-Talbott
OBJECTIVE: To provide a brief description of the pathophysiology of akathisia, the challenges of diagnosing and treating this condition, and potential associated clinical issues. Also, to provide a review of the literature on the incidence of drug-induced akathisia associated with the use of second-generation antipsychotics (SGAs) and first-generation antipsychotics (FGAs). DATA SOURCES: English-language literature with no date restrictions cited in PubMed was searched for the keywords akathisia, placebo, neuroleptic, or haloperidol, and the generic names of SGAs (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole)...
April 21, 2009: Journal of Clinical Psychiatry
https://read.qxmd.com/read/19351408/cost-effectiveness-model-comparing-olanzapine-and-other-oral-atypical-antipsychotics-in-the-treatment-of-schizophrenia-in-the-united-states
#17
JOURNAL ARTICLE
Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, Lee J Smolen, Anthony H Lawson, Robert R Conley, Steven D Culler
BACKGROUND: Schizophrenia is often a persistent and costly illness that requires continued treatment with antipsychotics. Differences among antipsychotics on efficacy, safety, tolerability, adherence, and cost have cost-effectiveness implications for treating schizophrenia. This study compares the cost-effectiveness of oral olanzapine, oral risperidone (at generic cost, primary comparator), quetiapine, ziprasidone, and aripiprazole in the treatment of patients with schizophrenia from the perspective of third-party payers in the U...
April 7, 2009: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/18947458/cost-effectiveness-of-atypical-antipsychotics-for-the-management-of-schizophrenia-in-the-uk
#18
MULTICENTER STUDY
Andrew Davies, Kawitha Vardeva, Jean-Yves Loze, Gilbert J L'italien, Karin Sennfalt, Marc van Baardewijk
OBJECTIVE: To evaluate the cost-effectiveness of atypical antipsychotic treatment sequences for the management of stable schizophrenia in the UK. RESEARCH DESIGN AND METHODS: A Markov model was developed to assess the cost per quality-adjusted life year (QALY) gained from 12 alternative treatment sequences each containing two of four atypical antipsychotics (aripiprazole, olanzapine, quetiapine and risperidone), followed by clozapine. The main model parameters were populated with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and a recent trial comparing aripiprazole with olanzapine...
November 2008: Current Medical Research and Opinion
https://read.qxmd.com/read/18344731/antipsychotic-induced-extrapyramidal-side-effects-in-bipolar-disorder-and-schizophrenia-a-systematic-review
#19
REVIEW
Keming Gao, David E Kemp, Stephen J Ganocy, Prashant Gajwani, Guohua Xia, Joseph R Calabrese
OBJECTIVES: Newer atypical antipsychotics have been reported to cause a lower incidence of extrapyramidal side effects (EPS) than conventional agents. This review is to compare antipsychotic-induced EPS relative to placebo in bipolar disorder (BPD) and schizophrenia. METHODS: English-language literature cited in Medline was searched with terms antipsychotics, placebo-controlled trial, and bipolar disorder or schizophrenia and then with antipsychotic (generic/brand name), safety, akathisia, EPS, or anticholinergic use, bipolar mania/depression, BPD, or schizophrenia, and randomized clinical trial...
April 2008: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/18211129/a-review-of-sensitivity-and-tolerability-of-antipsychotics-in-patients-with-bipolar-disorder-or-schizophrenia-focus-on-somnolence
#20
REVIEW
Keming Gao, Stephen J Ganocy, Prashant Gajwani, David J Muzina, David E Kemp, Joseph R Calabrese
OBJECTIVE: This study compared the sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia. DATA SOURCES: English-language literature from January 1966 to December 2006 cited in MEDLINE was searched for the terms antipsychotics, typical antipsychotics, atypical antipsychotic, generic and brand names of antipsychotics, safety, tolerability, discontinuation due to adverse events, somnolence, and bipolar mania, bipolar depression, bipolar disorder, manic-depressive illness, or schizophrenia, randomized, double blind, and controlled clinical trial...
February 2008: Journal of Clinical Psychiatry
keyword
keyword
86665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.